SECOND OPINION: BIG PHARMA’S EGREGIOUS PRICING PRACTICES AND ANTI-COMPETITIVE TACTICS ARE THE ROOT CAUSE OF HIGH DRUG PRICES

06-17-2024 Blog Posts

Breaking Down the Facts on Drug Prices, Innovation, Patent Abuse, Drug Company Profits and More from PhRMA’s Recent Comment Letter In a recent comment letter submitted to the U.S. Department of Health and Human Services (HHS), U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC), the Pharmaceutical Research and Manufacturers of America (PhRMA) sought to evade […]

DOSE OF REALITY: FORBES: MAKING IT HARDER TO CHALLENGE BIG PHARMA’S PATENT THICKETS WOULD RAISE DRUG PRICES, UNDERMINE TRUE INNOVATION

06-5-2024 Blog Posts

Research Article Explores Negative Implications of Proposal to Restrict Key Mechanism for Challenging Egregious Abuse of the Patent System Avik Roy, president of The Foundation for Research on Equal Opportunity (FREOPP),  is out with a new column in Forbes which examines a recent piece of legislation – “The Promoting and Respecting Economically Vital American Innovation […]

DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT HOPPING

05-23-2024 Blog Posts

Research Column Explores Case Study in Common Patent Abuse Tactic That Negatively Impacts Consumers, Extends Monopolies and Keeps Drug Prices High A new research column in Forbes this week explores case studies in one of Big Pharma’s most commonly used patent abuse tactics: product hopping. The column, authored by Forbes columnist and President of The […]

THEY SAID IT!: LAWMAKERS ROAST BIG PHARMA’S PATENT ABUSE, CALL FOR ACTION ON BIPARTISAN SOLUTIONS TO HOLD THE PHARMACEUTICAL INDUSTRY ACCOUNTABLE

05-22-2024 Blog Posts

Senate Judiciary Committee Puts Spotlight on Big Pharma’s Anti-Competitive Tactics that Extend Monopolies and Keep Drug Prices High On Tuesday, the U.S. Senate Committee on the Judiciary held a hearing titled “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market.” During the hearing, lawmakers from both sides of the aisle highlighted the […]

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

05-21-2024 Blog Posts

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Big Pharma Accountable for Anti-Competitive Tactics That Cost Patients and Taxpayers Billions of Dollars The U.S. Senate Committee on the Judiciary is scheduled to hold a hearing Tuesday, “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market.” Ahead of this important hearing, get a […]

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

05-16-2024 Blog Posts

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Blockbuster Products, Including Nearly 1,500 Patent Applications on Just Ten Drugs A new study, published in JAMA Network, examines Big Pharma’s egregious patent thickets erected around the top 10 best-selling prescription drugs in the U.S. The study found the top 10 brand name drugs in […]

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

05-10-2024 Blog Posts

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and Egregious GLP-1 Weight Loss Pricing Fueled 10 Percent Climb in U.S. Drug Spending A report released Tuesday from the IQVIA Institute for Human Data Science examines prescription drug spending in the U.S. in 2023 as well as projected spending trends through 2028. The findings demonstrate […]

BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER

05-6-2024 Blog Posts

Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost Profits for Big Pharma Giants at the Expense of American Patients Over the last week, several Big Pharma companies reported earnings that continued to outpace Wall Street expectations for the first quarter, driven by the brand name drug companies’ egregious anti-competitive practices and […]

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

05-2-2024 Blog Posts

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics, Result in Lower OOP Costs for Patients, and Produce Billions of Dollars in Savings Big Pharma deploys a full suite of tactics designed to game the U.S. patent system — enabling brand name drug companies to extend monopolies over their biggest money-makers. The pharmaceutical industry’s egregious abuse of […]

CSRXP APPLAUDS EXPANDED FTC CRACK DOWN ON BIG PHARMA’S SHAM PATENTS IN THE ORANGE BOOK

04-30-2024 Blog Posts

Commission Builds on Previous Action by Targeting More Than 300 Patents, Including on Blockbuster GLP-1 Weight Loss Drugs Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday reacting to an announcement from the Federal Trade Commission (FTC) that the Commission is challenging more than 300 patents listed in the U.S. Food and Drug Administration’s […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.